SLC35F4 inhibitors are a class of chemical compounds that target and block the activity of solute carrier family 35 member F4 (SLC35F4), a protein belonging to the SLC family, which is known for facilitating the transport of various molecules across cellular membranes. Although the specific biological role of SLC35F4 is not fully understood, it is believed to be involved in the transport of nucleotide sugars or other critical substrates within the endoplasmic reticulum or Golgi apparatus. These molecules are essential for processes such as glycosylation, where sugars are added to proteins and lipids, playing a vital role in cellular function and communication. SLC35F4 inhibitors are designed to bind to crucial regions of the protein, interfering with its transport activity and preventing the proper movement of substrates within the cell, thus altering cellular metabolism and biochemical pathways.
The process of developing SLC35F4 inhibitors requires a comprehensive understanding of the protein's structure and transport mechanism. Using techniques such as molecular modeling and crystallography, researchers identify specific binding pockets or active sites on SLC35F4 where inhibitors can interact. Once these sites are mapped, inhibitors are designed to fit these regions, effectively blocking the transporter's function without affecting similar proteins. The inhibitors are then evaluated through biochemical assays, measuring their ability to inhibit SLC35F4 activity and their selectivity towards this particular transporter. Studying SLC35F4 inhibitors allows researchers to investigate the transporter's exact role in cellular processes such as glycosylation and molecular trafficking, offering insights into how solute carrier proteins contribute to maintaining cellular balance and the overall coordination of metabolic pathways. By modulating the activity of SLC35F4, scientists can explore the broader implications of its function in cellular and molecular biology.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
A tyrosine kinase inhibitor that could indirectly affect SLC35F4 by altering signaling pathways involved in transporter regulation. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Known to inhibit calcineurin, potentially affecting the transcription and activity of certain solute carriers. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Disrupts Golgi apparatus structure and function, potentially impacting SLC35F4 localization and function. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Inhibits N-linked glycosylation, potentially affecting the maturation and function of glycoprotein-associated transporters like SLC35F4. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $48.00 $122.00 $432.00 $812.00 | 4 | |
Inhibits GLUT1, potentially altering cellular glucose levels and indirectly affecting SLC35F4 activity. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Activates adenylate cyclase, raising cAMP levels, which might influence SLC35F4 activity indirectly through signaling pathways. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
A carboxylic ionophore that disrupts intracellular ion gradients, possibly affecting SLC35F4-related transport mechanisms. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Inhibits mTOR signaling, which could indirectly affect the expression and function of various solute carriers, including SLC35F4. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
A glucose analog that inhibits glycolysis, potentially affecting cellular metabolism and indirectly SLC35F4 activity. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
Blocks calcium channels, which could indirectly influence the function of calcium-sensitive transporters and SLC35F4. | ||||||